Indonesia Pharmaceuticals & Healthcare Q4 2018
We do not expect Indonesia to achieve its goal of having universal healthcare by 2019. While significant progress hasbeen made in growing enrolment into the national health insurance scheme (JKN), further expansion will be hampered by deficit,investment shortages and uneven levels of healthcare access across the country. Additionally, for the pharmaceutical industry, theJKN's positive impact on growth is likely to wane over the medium term, as the scheme focuses on sales of low-cost generic drugs.Still, Indonesia's substantial population numbers, its epidemiological profile the emerging middle class will continue to offersignificant commercial opportunities for multinationals.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook